Ren et al. humanize and structurally optimize a chimeric anti-SFTSV antibody, generating variants with markedly enhanced neutralization potency by strengthening binding to recombinant Gn and intact virions, providing full in vivo protection and establishing a generalizable framework for therapeutic antibody engineering.